OWP Pharmaceuticals

OWP Pharmaceuticals delivers quality branded generic epilepsy medications that are replicable and fairly priced. Our strategic focus is to support neurologists and patients in the U.S. with beneficial products and to use the majority of the profits to provide resources for those living with epilepsy in under-resourced areas of the world, by donating to the ROW Foundation. How and why does OWP Pharmaceuticals strategically partner with the nonprofit ROW Foundation? OWP Pharmaceuticals was founded on drastically different values than most companies. It is not to maximize profits for shareholders, but instead to harness the power and efficiency of the free market to make the world a better place. We refer to this as Social Enterprise 2.0. We designed a two-track solution to reach our goals; a market-based company to harness the marketplace and a not-for-profit organization to direct this financial power to needy parts of the world. We are committed to excellence in all that we do. This means that best practices will always be a key benchmark. The linkage between the two organizations gives us the best of both worlds. Under its Corporate By-Laws, OWP is obligated to contribute the maximum charitable deduction allowed each year under IRS rules to the ROW Foundation. In addition to the annual charitable contribution, ROW has a "profit interest" in OWP. This profit interest legally requires that OWP distribute a majority of its annual dividends to the ROW Foundation. The ROW Foundation is not a short-term solution to a long-term problem. OWP is the sustainable, ongoing economic engine that financially underwrites the ROW Foundation's programs. As a shareholder of OWP, the Foundation is assured of its funding source long-term and as the company grows, so does the charitable work of ROW. Because the ROW Foundation is a shareholder of OWP Pharmaceuticals, this income is stable, dependable and under the control of the ROW Foundation Board of Directors. What does "One World.